physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health

Originally published in Applied Clinical Trials

physIQ has announced a strategic collaboration with InCarda Therapeutics, Inc. Syneos Health recommended physIQ’s monitoring solution to help advance InCarda’s clinical study of InRhythm™ (orally inhaled flecainide) in patients with atrial fibrillation.

Read more about the new partnership here.